Male Breast Cancer Clinical Trial
Official title:
Understanding Male Breast Cancer: Salah Azaïz Cancer Institute Experience
Verified date | August 2017 |
Source | Salah Azaïz Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The goal of this study is to evaluate the Salah Azaïz Cancer Institute male breast cancer
patients population over a period of 14 years.
Goal of the retrospective part: to gather clinicopathologic data and follow-up outcomes of
male breast cancer patients diagnosed and/or treated at Salah Azaïz Cancer Institute from
2004 to 2013.
Goal of the prospective part: to create a registry of male patients with breast cancer for a
period of 48 months (from 2014 to 2017).
Status | Active, not recruiting |
Enrollment | 150 |
Est. completion date | January 1, 2018 |
Est. primary completion date | December 31, 2016 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Histological diagnosis of male breast cancer |
Country | Name | City | State |
---|---|---|---|
Tunisia | Salah Azaïz Cancer Institute | Tunis |
Lead Sponsor | Collaborator |
---|---|
Salah Azaïz Cancer Institute |
Tunisia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical outcomes | Survival, Disease free survival | Through study completion, an average of 4 year | |
Primary | Clinico-biological characteristics of the disease | Through study completion, an average of 4 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02480933 -
Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens
|
N/A | |
Terminated |
NCT01705340 -
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
Terminated |
NCT01222377 -
Endoscopic Breast Surgery in Treating Patients With Breast Cancer
|
N/A | |
Completed |
NCT00244881 -
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
|
Phase 2 | |
Completed |
NCT00425672 -
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT00096434 -
Sorafenib in Treating Patients With Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00791037 -
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00559507 -
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00119262 -
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
|
Phase 2 | |
Completed |
NCT00098605 -
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
|
Phase 2 | |
Terminated |
NCT00095888 -
3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT00068588 -
GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT00071942 -
Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
|
Phase 1 | |
Recruiting |
NCT05501704 -
ETHAN - ET for Male BC
|
Phase 2 | |
Completed |
NCT02046421 -
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1 | |
Completed |
NCT01869764 -
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
|
Phase 2 | |
Completed |
NCT01720602 -
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
|
N/A | |
Completed |
NCT01493310 -
Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
|
Phase 1 |